https://orcid.org/0000-0003-2789-4289
References
- Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–4663.
- Caplin ME, Pavel M, Ćwikła JB, et al. for the CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.
- Pavel M, Valle JW, Eriksson B, et al. Antibes consensus conference participants; antibes consensus conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy - biotherapy and novel targeted agents. Neuroendocrinology. 2017;105(3):266–280.
- Pusceddu S, Rossi RE, Torchio M, et al. Differential diagnosis and management of diarrhea in patients with neuroendocrine tumors. J Clin Med. 2020;9(8):2468.
- Khan MS, Walter T, Buchanan-Hughes A, et al. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: a systematic review. World J Gastroenterol. 2020;26:4537–4556.
- Masoero G, Zaffino C, Laudi C, et al. Fecal pancreatic elastase 1 in the work up of patients with chronic diarrhea. Int J Pancreatol. 2000;28:175–179.
- Saif MW, Larson H, Kaley K, et al. Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin Drug Saf. 2010;9(6):867–873.
- Lamarca A, McCallum L, Nuttall C, et al. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Rev Gastroenterol Hepatol. 2018;12(7):723–731.
- Saif MW, Romano A, Smith MH. et al. Chronic use of long-acting somatostatin analogues (SSAs) and exocrine pancreatic insufficiency (EPI) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs): an under-recognized adverse effect. Cancer Med J. 2020;3(2):75–84.
- Rinzivillo M, De Felice I, Magi L, et al. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology. 2020;20(5):875–879.
- Vanga RR, Tansel A, Sidiq S, et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(8):1220–1228.e4.
- Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European calcified tissue society. Eur J Endocrinol. 2019;180:P23–P54.
- de Hosson LD, Stelwagen J, Bouma G, et al. Towards optimal personalized diet and vitamin supplementation in NET patients. Endocr Relat Cancer. 2018;25:L23–L26.
- Maasberg S, Knappe-Drzikova B, Vonderbeck D, et al. Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia. Neuroendocrinology. 2017;104:11–25.
- Fiebrich HB, Van Den Berg G, Kema IP, et al. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Aliment Pharmacol Ther. 2010;32:1398–1404.
- Dominguez-Munoz JE, Drewes AM, Lindkvist B, et al. HaPanEU/UEG working group. Recommendations from the United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. Pancreatology. 2018;18(8):847–854.
- Barkin JA, Westermann A, Hoos W, et al. Frequency of appropriate use of pancreatic enzyme replacement therapy and symptomatic response in pancreatic cancer patients. Pancreas. 2019;48(6):780–786.
- Magi L, Mazzuca F, Rinzivillo M, et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med. 2019;8(6):910.